WHAT IS CLAIMED:

1. A bispecific antibody that specifically binds to *Pseudomonas aeruginosa* PcrV protein and Psl exopolysaccharide, wherein the antibody comprises a modified IgG Fc region, the modified IgG Fc region comprising amino acid substitutions at two or more of positions 432 to 437, numbered according to the EU numbering index of Kabat, relative to a wild-type IgG Fc region; wherein

(i) positions 432 and 437 are each substituted with cysteine;

(ii) position 433 is histidine or is substituted with arginine, proline, threonine, lysine, serine, alanine, methionine, or asparagine;

(iii) position 434 is asparagine or is substituted with arginine, tryptophan, histidine, phenylalanine, tyrosine, serine, methionine or threonine;

(iv) position 435 is histidine; and

(v) position 436 is tyrosine or phenylalanine or is substituted with leucine, arginine, isoleucine, lysine, methionine, valine, histidine, serine, or threonine; and

wherein the antibody has an increased half-life compared to the half-life of a corresponding antibody having the wild-type IgG Fc region.

2. The bispecific antibody of claim 1, wherein the modified IgG Fc region is a modified IgG1 Fc region.

3. The bispecific antibody of claim 1 or 2, wherein the modified IgG Fc region is a modified human IgG Fc region.

4. The bispecific antibody of any one of claims 1-3, wherein the bispecific antibody exhibits less aggregation in solution than an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.

5. The bispecific antibody of any one of claims 1-4, wherein the bispecific antibody promotes opsonophagocytic killing activity of *P. aeruginosa,* optionally wherein the bispecific antibody mediates similar *in vitro* opsonophagocytic killing activity of *P. aeruginosa* as an antibody comprising a heavy chain comprising the amino acid sequence

of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.

6. The bispecific antibody of any one of claims 1-5, further comprising an amino acid insertion after position 437, optionally wherein the amino acid insertion is glutamic acid.

7. The bispecific antibody of any one of claims 1-6, wherein the binding affinity of the bispecific antibody for FcRn at pH 6.0 is higher than the binding affinity for FcRn of a corresponding antibody having the wild-type human IgG1 Fc region at pH 6.

8. The bispecific antibody of any one of claims 1-7, wherein the binding affinity of the bispecific antibody for FcRn at pH 7.4 is higher than the binding affinity for FcRn of a corresponding antibody having the wild-type human IgG1 Fc region at pH 7.4.

9. The bispecific antibody of any one of claims 1-8, wherein the modified human IgG1 Fc region exhibits increased pH dependence on binding affinity for FcRn compared to a corresponding antibody having the wild-type human IgG1 Fc region.

10. The bispecific antibody of any one of claims 1-9, wherein the modified human IgG1 Fc region has amino acid substitutions at three of positions 432, 433, 434, 435, 436, and 437.

11. The bispecific antibody of any one of claims 1-9, wherein the modified human IgG1 Fc region has amino acid substitutions at four of positions 432, 433, 434, 435, 436, and 437.

12. The bispecific antibody of any one of claims 1-9, wherein the modified human IgG1 Fc region has amino acid substitutions at five of positions 432, 433, 434, 435, 436, and 437.

13. The bispecific antibody of any one of claims 1-9, wherein the modified human IgG1 Fc region has amino acid substitutions at six of positions 432, 433, 434, 435, 436, and 437.

14. The bispecific antibody of any one of claims 1-9, wherein the modified human IgG1 Fc region comprises the amino acid sequence of SEQ ID NO:44 or the amino acid sequence of SEQ ID NO:33.

15. The bispecific antibody of any one of claims 1-14, wherein the bispecific antibody is not a HexaBody.

16. The bispecific antibody of any one of claims 1-15, wherein the bispecific antibody competitively inhibits binding to PcrV of an antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:13 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:14.

17. The bispecific antibody of any one of claims 1-16, wherein the bispecific antibody binds to the same epitope of PcrV as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:13 and a VL comprising the amino acid sequence of SEQ ID NO:14.

18. The bispecific antibody of any one of claims 1-17, wherein the bispecific antibody comprises an antigen-binding domain that binds to *Pseudomonas aeruginosa* PcrV protein and comprises a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:1, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:2, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:4, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:6.

19. The bispecific antibody of claim 18, wherein the antigen-binding domain that binds to *Pseudomonas aeruginosa* PcrV protein comprises a VH comprising the amino acid sequence of SEQ ID NO:13 and/or a VL comprising the amino acid sequence of SEQ ID NO:14.

20. The bispecific antibody of claim 18 or claim 19, wherein the antigen-binding domain that binds to *Pseudomonas aeruginosa* PcrV protein comprises a heavy chain variable region and a light chain variable region on separate polypeptides.

21. The bispecific antibody of any one of claims 1-20, wherein the bispecific antibody competitively inhibits binding to Psl of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:15 and a VL comprising the amino acid sequence of SEQ ID NO:16.

22. The bispecific antibody of any one of claims 1-21, wherein the bispecific antibody binds to the same epitope of Psl as an antibody comprising a VH comprising the amino acid

sequence of SEQ ID NO:15 and a VL comprising the amino acid sequence of SEQ ID NO:16.

23. The bispecific antibody of any one of claims 1-22, wherein the antibody comprises an antigen-binding domain that binds to *Pseudomonas aeruginosa* Psl exopolysaccharide and comprises a heavy chain variable region VH-CDR1 comprising the amino acid sequence of SEQ ID NO:7, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:8, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:9, a light chain variable region VL-CDR1 comprising the amino acid sequence of SEQ ID NO:10, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:11, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:12.

24. The bispecific antibody of claim 23, wherein the antigen-binding domain that binds to *Pseudomonas aeruginosa* Psl exopolysaccharide comprises a VH comprising the amino acid sequence of SEQ ID NO:15 and/or a VL comprising the amino acid sequence of SEQ ID NO:16.

25. The bispecific antibody of claim 23 or 24, wherein the antigen-binding domain that binds to *Pseudomonas aeruginosa* Psl exopolysaccharide comprises a VH and a VL on the same polypeptide.

26. The bispecific antibody of any one of claims 23-25, wherein the antigen-binding domain that binds to *Pseudomonas aeruginosa* Psl exopolysaccharide comprises a linker between the VH and the VL, optionally wherein the linker comprises the amino acid sequence of SEQ ID NO:18.

27. The bispecific antibody of any one of claims 23-26, wherein the antigen-binding domain that binds to *Pseudomonas aeruginosa* Psl exopolysaccharide comprises an scFv.

28. The bispecific antibody of claim 27, wherein the scFv comprises a linker, optionally wherein the linker comprises the amino acid sequence of SEQ ID NO:18.

29. The bispecific antibody of claim 27 or claim 28, wherein the scFv is in the orientation VH-linker-VL.

30. The bispecific antibody of any one of claims 27-29, wherein the scFv comprises the amino acid sequence of SEQ ID NO:17.

31. The bispecific antibody of any one of claims 27-30, wherein the scFv is on the same polypeptide chain as the VH of the antigen-binding domain that binds to *Pseudomonas aeruginosa* PcrV protein.

32. The bispecific antibody of any one of claims 27-31, wherein the scFv is C-terminal to the VH of the antigen-binding domain that binds to *Pseudomonas aeruginosa* PcrV protein.

33. The bispecific antibody of any one of claims 1-32, wherein the bispecific antibody comprises (i) a heavy chain of the formula VH-CH1-H1-L1-S-L2-H2-CH2-CH3, wherein VH is an anti-*Pseudomonas aeruginosa* PcrV heavy chain variable domain; CH1 is a heavy chain constant region domain 1; H1 is a first heavy chain hinge region fragment; L1 is a first linker; S is an anti-*Pseudomonas aeruginosa* Psl scFv molecule; L2 is a second linker; H2 is a second heavy chain hinge region fragment; CH2 is a heavy chain constant region domain-2; and CH3 is a heavy chain constant region domain-3; and (ii) a light chain of the formula VL-CL, wherein VL is an anti-*Pseudomonas aeruginosa* PcrV light chain variable domain, and CL is an antibody light chain kappa constant region or an antibody light chain lambda constant region.

34. The bispecific antibody of claim 33, wherein CH1 comprises the amino acid sequence of SEQ ID NO:21.

35. The bispecific antibody of claim 33 or claim 34, wherein H1 comprises the amino acid sequence of SEQ ID NO:22.

36. The bispecific antibody of any one of claims 33-35, wherein L1 comprises the amino acid sequence of SEQ ID NO:28.

37. The bispecific antibody of any one of claims 33-36, wherein L2 comprises the amino acid sequence of SEQ ID NO:28.

38. The bispecific antibody of any one of claims 33-37, wherein H2 comprises the amino acid sequence of SEQ ID NO:23.

39. The bispecific antibody of any one of claims 33-38, wherein CH2-CH3 comprises the amino acid sequence of SEQ ID NO:30.

40. The bispecific antibody of any one of claims 33-39, wherein CL is an antibody light chain kappa constant region.

41. The bispecific antibody of any one of claims 33-40, wherein CL comprises the amino acid sequence of SEQ ID NO:24.

42. The bispecific antibody of any one of claims 1-41, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:31 and/or a light chain comprising the amino acid sequence of SEQ ID NO:20.

43. An isolated polynucleotide comprising a nucleic acid molecule encoding the heavy chain of the bispecific antibody of any one of claims 1-42.

44. The isolated polynucleotide of claim 43, further comprising a nucleic acid molecule encoding the light chain of the bispecific antibody of any one of claims 1-42.

45. A vector comprising the polynucleotide of claim 43 or 44.

46. A host cell comprising (i) the polynucleotide of claim 43 or 44, or (ii) the vector of claim 45.

47. A method of producing a bispecific antibody, the method comprising culturing the host cell of claim 46, and optionally isolating the bispecific antibody.

48. A bispecific antibody produced by the method of claim 47.

49. A composition comprising the bispecific antibody of any one of claims 1-42 or 48, and a pharmaceutically acceptable carrier.

50. Use of the bispecific antibody of any one of claims 1-42 or 48, or the composition of claim 49, in the preparation of a medicament for use in a method of treating or preventing a *Pseudomonas* infection in a subject in need thereof.

51. The use of claim 50, wherein the infection is a lung infection, a respiratory tract infection, pneumonia, bacteremia, a bone infection, a joint infection, a skin infection, a burn infection, a wound infection, or any combination thereof.

52. Use of the bispecific antibody of any one of claims 1-42 or 48, or the composition of claim 49, in the preparation of a medicament for use in a method of treating bronchiectasis in a subject in need thereof.

53. Use of the bispecific antibody of any one of claims 1-42 or 48, or the composition of claim 49, in the preparation of a medicament for use in a method of improving pre-bronchodilator forced expiratory volume 1 (FEV_1) in a subject with bronchiectasis.

54. Use of the bispecific antibody of any one of claims 1-42 or 48, or the composition of claim 49, in the preparation of a medicament for use in a method of reducing *Pseudomonas aeruginosa* load in a subject with bronchiectasis.

55. Use of the bispecific antibody of any one of claims 1-42 or 48, or the composition of claim 49, in the preparation of a medicament for use in a method of reducing bronchiectasis exacerbations in a subject in need thereof.

56. Use of the bispecific antibody of any one of claims 1-42 or 48, or the composition of claim 49, in the preparation of a medicament for use in a method of reducing the need for intravenous antibiotics in a subject with bronchiectasis.

57. Use of the bispecific antibody of any one of claims 1-42 or 48, or the composition of claim 49, in the preparation of a medicament for use in a method of stabilizing lung function in a subject with bronchiectasis.

58. The use of any one of claims 52-57, wherein the bronchiectasis is non-cystic fibrosis bronchiectasis.

59. The use of any one of claims 50-58, further comprising administering an antibiotic.

60. The use of any one of claims 50-59, wherein the subject is colonized with *Pseudomonas aeruginosa*.